Teva Pharmaceutical Industries Limited filed its quarterly report on Form 10-Q with the SEC on November 3, 2026, covering the period ended September 30, 2026, and reporting 1,166,826,784 ordinary shares outstanding as of that date.

Key Highlights

  • Shares outstanding: As of September 30, 2026, the company had 1,166,826,784 ordinary shares outstanding, each with a par value of NIS 0.10 per share.
  • Exchange listing: Ordinary shares are registered on the New York Stock Exchange under the trading symbol TEVA (NYSE:TEVA).
  • Large accelerated filer: The company is classified as a large accelerated filer, according to the filing.
  • U.S. Administration agreement: The filing references "an agreement we entered with the U.S. Administration in October 2026, on the pricing and sales of our products, manufacturing and the availability of raw materials."
  • Planned API divestiture: The filing identifies a "planned divestiture of our API business" as a factor relevant to the company's prospects.
  • Pivot to Growth strategy: The company cites its ability to "successfully execute on our Pivot to Growth strategy" as a forward-looking risk factor, including expansion of innovative and biosimilar medicines pipelines.

Teva Discloses October 2026 U.S. Administration Agreement in Third-Quarter Report

Teva Pharmaceutical Industries Limited, incorporated in Israel and headquartered at 400 Interpace Parkway, #3, Parsippany, NJ 07054, filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 3, 2026. The company trades on the New York Stock Exchange under the symbol NYSE:TEVA. According to the filing, the company had 1,166,826,784 ordinary shares outstanding as of September 30, 2026, each carrying a par value of NIS 0.10 per share.

Among the risk factors disclosed, the filing specifically references "the agreement we entered with the U.S. Administration in October 2026, on the pricing and sales of our products, manufacturing and the availability of raw materials," citing it as a factor that could affect results. The filing also identifies a "planned divestiture of our API business" in the context of risks related to asset sales and plant closures. The company characterizes its ability to execute its "Pivot to Growth strategy" - including expanding its innovative and biosimilar medicines pipeline and achieving cost savings through organizational transformation - as subject to material uncertainty.

The filing also notes risks from ongoing global conflicts, including "in the Middle East and war involving Iran," as well as "the war between Russia and Ukraine," and flags potential effects of international trade policies, including the imposition of tariffs in jurisdictions where the company operates. The report contains forward-looking statements that, according to the filing's cautionary language, are "subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly."

What Was Disclosed

Teva filed a Form 10-Q for the quarter ended September 30, 2026, disclosing 1,166,826,784 ordinary shares outstanding, an October 2026 agreement with the U.S. Administration on product pricing and manufacturing, a planned API business divestiture, and a range of operational and geopolitical risk factors.